Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535–46.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Konig D, Savic Prince S, Rothschild SI. Targeted therapy in advanced and metastatic non-small cell lung cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations. Cancers (Basel). 2021;13:804.

Article  PubMed  PubMed Central  Google Scholar 

Tan AC, Tan DSW. Targeted therapies for lung cancer patients with oncogenic driver molecular alterations. J Clin Oncol. 2022;40:611–25.

Article  CAS  PubMed  Google Scholar 

Fang L, Zhao W, Ye B, Chen D. Combination of immune checkpoint inhibitors and anti-angiogenic agents in brain metastases from non-small cell lung cancer. Front Oncol. 2021;11:670313.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Passaro A, Janne PA, Peters S. Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J Clin Oncol. 2023;41:3747–61.

Article  PubMed  Google Scholar 

Salifu I, Singh N, Berraondo M, Remon J, Salifu S, Severson E, et al. Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer. Cancer Treat Res Commun. 2023;36:100713.

Article  PubMed  Google Scholar 

Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713.

Article  CAS  PubMed  Google Scholar 

Pettinato MC. Introduction to antibody-drug conjugates. Antibodies (Basel). 2021;10:42.

Article  CAS  PubMed  Google Scholar 

Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, Le X. Antibody-drug conjugates in lung cancer: dawn of a new era? NPJ Precis Oncol. 2023;7:5.

Article  PubMed  PubMed Central  Google Scholar 

Jin Y, Schladetsch MA, Huang X, Balunas MJ, Wiemer AJ. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022;229:107917.

Article  CAS  PubMed  Google Scholar 

Theocharopoulos C, Lialios PP, Samarkos M, Gogas H, Ziogas DC. Antibody-drug conjugates: functional principles and applications in oncology and beyond. Vaccines (Basel). 2021;9:1111.

Article  CAS  PubMed  Google Scholar 

Samantasinghar A, Sunildutt NP, Ahmed F, Soomro AM, Salih ARC, Parihar P, et al. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate. Biomed Pharmacother. 2023;161:114408.

Article  CAS  PubMed  Google Scholar 

Marei HE, Cenciarelli C, Hasan A. Potential of antibody-drug conjugates (ADCs) for cancer therapy. Cancer Cell Int. 2022;22:255.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Joubert N, Beck A, Dumontet C, Denevault-Sabourin C. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel). 2020;13:245.

Article  CAS  PubMed  Google Scholar 

Chen H, Lin Z, Arnst KE, Miller DD, Li W. Tubulin inhibitor-based antibody-drug conjugates for cancer therapy. Molecules. 2017;22:1281.

Article  PubMed  PubMed Central  Google Scholar 

Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710–9.

Article  CAS  PubMed  Google Scholar 

McKertish CM, Kayser V. Advances and limitations of antibody drug conjugates for cancer. Biomedicines. 2021;9:872.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu J, Jiang F, Lu A, Zhang G. Linkers having a crucial role in antibody-drug conjugates. Int J Mol Sci. 2016;17:561.

Article  PubMed  PubMed Central  Google Scholar 

Boghaert ER, Cox MC, Vaidya KS. Pathophysiologic and pharmacologic considerations to improve the design and application of antibody-drug conjugates. Cancer Res. 2022;82:1858–69.

Article  CAS  PubMed  Google Scholar 

Menon S, Parakh S, Scott AM, Gan HK. Antibody-drug conjugates: beyond current approvals and potential future strategies. Explor Target Antitumor Ther. 2022;3:252–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riudavets M, Sullivan I, Abdayem P, Planchard D. Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open. 2021;6:100260.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146:264–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209.

Article  PubMed  PubMed Central  Google Scholar 

Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li BT, Michelini F, Misale S, Cocco E, Baldino L, Cai Y, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020;10:674–87.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, et al. A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer. J Thorac Oncol. 2018;13:273–9.

Article  CAS  PubMed  Google Scholar 

Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, et al. Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers. Clin Cancer Res. 2019;25:64–72.

Article  CAS  PubMed  Google Scholar 

Iwama E, Zenke Y, Sugawara S, Daga H, Morise M, Yanagitani N, et al. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. Eur J Cancer. 2022;162:99–106.

Article  CAS  PubMed  Google Scholar 

Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on trastuzumab deruxtecan (DS-8201, T-DXd) for HER2 mutation positive non-small cell lung cancer. Lung Cancer (Auckl). 2021;12:103–14.

PubMed  Google Scholar 

Tsurutani J, Iwata H, Krop I, Janne PA, Doi T, Takahashi S, et al. Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors. Cancer Discov. 2020;10:688–701.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241–51. A multicenter, international, phase 2 study showed that trastuzumab deruxtecan had durable anticancer activity in patients with HER2-mutant NSCLC.

Article  CAS  PubMed  Google Scholar 

Passaro A, Peters S. Targeting HER2-mutant NSCLC - the light is on. N Engl J Med. 2022;386:286–9.

Article  CAS  PubMed  Google Scholar 

Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.

Article  PubMed  PubMed Central  Google Scholar 

Goto K, Sang-We K, Kubo T, Goto Y, Ahn M, Planchard D, et al. LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): interim results from the phase 2 DESTINY-Lung02 trial. Ann Oncol. 2022;33:S1422.

Article  Google Scholar 

Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–9006.

Article  PubMed  PubMed Central